Europe In Vitro Diagnostics Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The European IVD market sits at the heart of routine clinical decision-making, supporting hospitals, independent laboratories, and increasingly decentralized testing sites across the region. Despite heterogeneity among national healthcare systems, IVD spending is a consistent component of total laboratory and pathology expenditure in Western, Central, and Northern Europe. The market is moving toward integrated platforms that combine reagents, analyzers, and data management, reflecting a broader shift from standalone tests to connected diagnostic ecosystems.

• •2025 market size of approximately $30.73 billion with ~4.87% CAGR over the forecast horizon.
• •Reagents and consumables dominate revenue mix due to recurring demand across routine and specialized assays.
• •Adoption is broadening beyond central labs into physician offices, pharmacies, and at-home self-testing settings.

Demographic aging, the sustained burden of cancer, diabetes, cardiovascular disease, and infectious disease screening programs continue to anchor test volume growth. Decentralization of care and the rollout of point-of-care platforms are shortening turnaround times and enabling earlier intervention. Regulatory momentum behind companion diagnostics and value-based reimbursement is encouraging uptake of advanced molecular and immunoassay tests tied to therapeutic selection.

• •Rising chronic and infectious disease prevalence expands routine testing demand.
• •Point-of-care and self-test solutions increase access outside hospital laboratories.
• •Companion diagnostics for targeted therapies accelerates molecular test adoption.

By technology, immunoassays historically represent the largest revenue share, with molecular diagnostics growing fastest on the back of infectious disease, oncology, and genetic testing demand. By end user, hospital laboratories retain the largest share, followed by independent reference labs, clinics, and home/self-testing. Geographically, Germany, France, the United Kingdom, Italy, and Spain contribute the majority of regional revenue, while Central and Eastern European markets are growing from a smaller base as diagnostic infrastructure modernizes.

• •Immunoassays lead by technology; molecular diagnostics is the fastest-growing segment.
• •Hospital and reference labs dominate end-use, with point-of-care and self-testing rising quickly.
• •Western European countries lead revenue, while Central and Eastern Europe offer higher percentage growth potential.

What are the recent trends and outlook?

Automation, AI-assisted result interpretation, and laboratory consolidation are reshaping the European diagnostics value chain, while multiplex testing is gaining traction in respiratory, sexually transmitted infection, and oncology panels. Post-pandemic investment in respiratory pathogen surveillance, antimicrobial resistance monitoring, and pandemic preparedness is sustaining demand for molecular workflows. The outlook points toward continued mid-single-digit expansion, with growth tilting toward decentralized, digitally enabled, and molecularly driven testing over traditional immunoassay and clinical chemistry categories.

• •AI-enabled image and data analysis is being embedded across histology, microbiology, and immunoassay platforms.
• •Multiplex and syndromic panels are displacing sequential single-pathogen testing in clinical workflows.
• •Sustained public and private investment in infectious disease preparedness supports long-term molecular testing demand.